Drug intelligence / Profile preview

Aliviador

Development stage
Phase 3
Lead developer
Nanjing Baijingyu Pharmaceutical
Modality
Small Molecules
Administration
Topical
01

Overview

**Aliviador** is a Brazilian topical fixed-dose counterirritant and analgesic product containing methyl salicylate, camphor, menthol, and turpentine essence. It is applied locally for symptomatic relief of rheumatic, neuralgic, muscular, and traumatic pain, including contusions and torticollis. Its components produce local cooling, rubefacient, irritant, and mild local anesthetic effects intended to reduce perceived musculoskeletal pain. A Laboratório Brasileiro de Biologia-sponsored Phase 3 trial evaluated Aliviador against Gelol in contusions, sprains, trauma, muscle injury, myalgia, myofascial pain, and tendinitis. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01097798))

Brand names
Aliviador
Other names
salicilato de metila + cânfora + mentol + essência de terebintina
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on Aliviador.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aliviador.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call